Hansa Biopharma — Juni 2025
-
Hansa Biopharma rejser kapital via emission og konvertergæld for at sikre finansiering af sine to store fase III‑studier i 2025–26 og omlægge gælden med NovaQuest, samtidig med at udvande eksisterende aktieejere med ca. 20 % https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-has-carried-out-a-directed-cash-share-issue-of-approx-msek-232-and-entered-into-binding-agreement-to-restructure-debt-held-by-novaquest-including-set-off-issue-of-usd-14-9-million/
-
"Far from its previous peaks, the biotech sector is now trading at the same levels it reached back in 2015.
That’s a full decade of underperformance, an anomaly in a market driven by innovation, disruption, and long-term growth". Læs mere i denne tråd fra X: https://x.com/nataninvesting/status/1938931955422113924
-
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-presents-positive-outcomes-of-five-year-follow-up-study-of-imlifidase-in-kidney-transplantation-at-esot-congress-2025-in-london/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind